Jan Vishwas Bill to Transform Health Sector with Penalty Reforms

The Union Health Ministry has hailed the recently passed Jan Vishwas Bill as a major step for public health. The bill amends several key health laws, including the Drugs and Cosmetics Act, to replace imprisonment for minor procedural lapses with monetary penalties. A central feature is the introduction of a formal adjudication mechanism to handle such violations outside the court system. These reforms aim to reduce litigation burdens, provide regulatory clarity, and foster a more facilitative environment for the health sector.

Key Points: Jan Vishwas Bill: Health Sector Compliance Reforms

  • Replaces jail with fines for minor violations
  • Introduces civil adjudication mechanism
  • Streamlines 5 key health laws
  • Aims to reduce regulatory fragmentation
3 min read

Jan Vishwas Bill's provisions promise big boost to health sector: Ministry​

The Jan Vishwas Bill replaces criminal penalties with fines for minor health sector violations, easing compliance and reducing court burdens.

"This reform will significantly reduce the burden on courts, minimise layers of litigation - Health Ministry Statement"

New Delhi, April 3

The Union Ministry of Health and Family Welfare on Friday hailed the Jan Vishwas Bill, 2026, recently passed by both Houses of Parliament, as a significant step to safeguard public health.​

As per the provisions of the Bill, 784 provisions across 79 Central Acts administered by 23 Ministries have been amended.​

Within the health sector, the amendments span key legislations including the Drugs and Cosmetics Act, 1940; the Pharmacy Act, 1948; the Food Safety and Standards Act; the Clinical Establishments (Registration and Regulation) Act, 2010; and the National Commission for Allied and Healthcare Professions Act, 2021, said a statement.​

These reforms align with the broader objective of simplifying compliance while maintaining robust safeguards for public health, it said.​

A central feature of these reforms is the replacement of criminal penalties, particularly imprisonment for minor procedural violations, with graded monetary penalties.​

This marks a shift towards a more facilitative regulatory framework while retaining strict action for serious violations affecting public health and safety.​

Under the Drugs and Cosmetics Act, 1940, several provisions have been amended to substitute imprisonment with financial penalties and to introduce a structured adjudication mechanism, the statement said.​

Notably, an adjudication mechanism has been introduced for violations under Section 27A(ii) and Section 28A. This ensures that minor cosmetic violations (other than spurious or adulterated products) will not require court intervention and can instead be addressed through a civil penalty framework.​

Further, violations such as non-maintenance of documents or non-submission of information, which were earlier punishable through court-imposed fines or imprisonment, can now be adjudicated through this civil penalty mechanism.​

For the first time, the legislation provides for the appointment of adjudicating authorities by the Central Government and State Governments, along with a defined process that includes the issuance of show-cause notices, provision for personal hearings, and an appellate mechanism.​

This reform will significantly reduce the burden on courts, minimise layers of litigation, and enable faster resolution of minor compliance issues, said the statement.​

It will particularly benefit the cosmetics industry by enabling structured, predictable handling of minor infringements, including procedural lapses such as failure to maintain statutory records or documents, thereby freeing them from prolonged litigation.​

Similarly, amendments to the Pharmacy Act, 1948, aim to modernise penalty provisions and enhance accountability through increased financial penalties for non-compliance. The reforms also ensure alignment with updated legal frameworks, it said.​

Under the Food Safety and Standards Act, 2006, provisions have been streamlined to strengthen enforcement while ensuring that penalties are proportionate to the nature of the offence. This supports a balanced approach between regulatory oversight and ease of compliance.​

The Clinical Establishments (Registration and Regulation) Act, 2010, has been updated to emphasise monetary penalties for non-compliance, particularly in cases where deficiencies do not pose immediate risks to patient safety. This encourages corrective action without resorting to criminal proceedings, the statement said.​

Further, the National Commission for Allied and Healthcare Professions Act, 2021, has been strengthened to ensure compliance with professional standards and regulatory requirements, with penalties designed to deter violations while maintaining proportionality.​

The alignment of these reforms across multiple health-related legislations reflects a coherent policy approach aimed at harmonising regulatory frameworks, it said.​

By standardising the shift from criminal penalties to civil penalties and introducing adjudication mechanisms, the amendments ensure consistency, predictability, and proportionality in enforcement. ​

This alignment reduces regulatory fragmentation, simplifies compliance requirements, and provides clarity to stakeholders operating across different segments of the health sector.​

- IANS

Share this article:

Reader Comments

R
Rajesh Q
Good move on paper, but implementation is key. Who will these 'adjudicating authorities' be? If they are just retired bureaucrats, it might become another avenue for corruption. The government must ensure transparency in this new system. The reduction in court burden is a definite plus though.
D
David E
As someone in the medical devices import business, this is a huge relief. The fear of accidental non-compliance leading to criminal charges was always there. A structured penalty system will allow us to operate without that constant anxiety. Hope states adopt this uniformly.
A
Ananya R
While easing business is good, I hope patient safety isn't compromised. The line between a 'minor procedural lapse' and something that can harm people can be thin. Strict action must remain for adulterated food and fake medicines. The bill seems to balance it, but vigilance is needed.
K
Karthik V
Finally! Harmonising 79 different acts is a mammoth task. This should reduce the confusion for healthcare entrepreneurs. One clear rulebook instead of navigating a maze of old laws will boost investment in the sector. Ease of doing business is crucial for 'Make in India' in pharma.
S
Sarah B
The focus on the cosmetics industry is interesting. It's a fast-growing sector in India. Freeing them from prolonged litigation over minor record-keeping issues will help Indian brands compete globally. More predictable regulations attract investment.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50